HC Wainwright Issues Negative Estimate for BTAI Earnings

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) – HC Wainwright cut their Q2 2025 earnings per share estimates for shares of BioXcel Therapeutics in a research note issued to investors on Monday, June 23rd. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($2.30) per share for the quarter, down from their previous forecast of ($2.24). The consensus estimate for BioXcel Therapeutics’ current full-year earnings is ($24.39) per share. HC Wainwright also issued estimates for BioXcel Therapeutics’ Q3 2025 earnings at ($2.57) EPS, Q4 2025 earnings at ($1.68) EPS, FY2025 earnings at ($8.03) EPS and FY2026 earnings at ($2.17) EPS.

Several other analysts have also issued reports on BTAI. RODMAN&RENSHAW raised BioXcel Therapeutics to a “strong-buy” rating in a report on Wednesday, March 19th. Wall Street Zen raised BioXcel Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 6th. Finally, Rodman & Renshaw began coverage on BioXcel Therapeutics in a report on Wednesday, March 19th. They set a “buy” rating and a $65.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, BioXcel Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $42.60.

BioXcel Therapeutics Price Performance

Shares of NASDAQ BTAI opened at $2.03 on Wednesday. The stock’s fifty day moving average price is $1.62 and its two-hundred day moving average price is $3.09. BioXcel Therapeutics has a one year low of $1.17 and a one year high of $23.04. The firm has a market cap of $12.30 million, a price-to-earnings ratio of -0.15 and a beta of -0.12.

BioXcel Therapeutics (NASDAQ:BTAI) last posted its earnings results on Monday, May 12th. The company reported ($1.50) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.72) by $1.22. The business had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.35 million.

Hedge Funds Weigh In On BioXcel Therapeutics

Several large investors have recently bought and sold shares of BTAI. Squarepoint Ops LLC raised its position in shares of BioXcel Therapeutics by 203.9% during the fourth quarter. Squarepoint Ops LLC now owns 72,046 shares of the company’s stock worth $27,000 after acquiring an additional 48,336 shares during the last quarter. Northern Trust Corp raised its position in shares of BioXcel Therapeutics by 81.4% during the fourth quarter. Northern Trust Corp now owns 73,910 shares of the company’s stock worth $28,000 after acquiring an additional 33,161 shares during the last quarter. Goldman Sachs Group Inc. bought a new position in shares of BioXcel Therapeutics during the first quarter worth about $50,000. Wells Fargo & Company MN raised its position in shares of BioXcel Therapeutics by 7.5% during the fourth quarter. Wells Fargo & Company MN now owns 199,010 shares of the company’s stock worth $74,000 after acquiring an additional 13,952 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of BioXcel Therapeutics by 4.7% during the fourth quarter. Geode Capital Management LLC now owns 311,965 shares of the company’s stock worth $117,000 after acquiring an additional 13,922 shares during the last quarter. 30.68% of the stock is currently owned by institutional investors.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.